Erschienen in:
01.07.2015 | Original Article
Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia
verfasst von:
Naohiro Watanabe, Seiji Niho, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Hironobu Ohmatsu, Koichi Goto
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 1/2015
Einloggen, um Zugang zu erhalten
Abstract
Purpose
The role of second-line chemotherapy in patients with non-small cell lung cancer (NSCLC) and preexisting interstitial pneumonia (IP) previously treated with platinum-based chemotherapy remains uncertain. This study was conducted to elucidate the efficacy and tolerability of second-line docetaxel monotherapy for patients with platinum-refractory advanced (stage IIIB, IV, or relapse) NSCLC and preexisting IP.
Methods
A total of 35 patients (median age, 67 years) treated with docetaxel monotherapy in a second-line setting following first-line platinum-based chemotherapy between January 2002 and December 2013 were retrospectively reviewed.
Results
The overall response rate and disease control rate were 8.6 % [95 % confidence interval (CI) 0–17.9 %] and 37.1 % (95 % CI 21.1–53.1 %), respectively. The median progression-free survival and median overall survival periods were 1.6 months (95 % CI 1.2–2.0 months) and 5.1 months (95 % CI 3.2–6.7 months), respectively. The incidence of acute exacerbation (AE) of IP following docetaxel monotherapy was 14.3 % (5/35 patients). Of the five patients who developed AE of IP, three patients died. The toxicity of this regimen was substantial, with treatment-related deaths occurring in 5 (14.3 %) patients (AE of IP: 3, sepsis: 2).
Conclusions
Docetaxel monotherapy has a poor activity and substantial risks when used for the treatment of platinum-resistant NSCLC with IP. Novel therapeutic approaches should be explored in this setting.